Corpus Intelligence IC Memo — CITY OF HOPE NATIONAL MEDICAL CTR 2026-04-26 03:51 UTC
IC Memo — CITY OF HOPE NATIONAL MEDICAL CTR
Investment Committee Memorandum | CA | 217 beds | Grade B | EBITDA uplift $134.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

CITY OF HOPE NATIONAL MEDICAL CTR

CCN 050146 | LOS ANGELES, CA | 217 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

CITY OF HOPE NATIONAL MEDICAL CTR is a 217-bed large academic medical center in LOS ANGELES, CA with $1.83B in net patient revenue and a -10.7% operating margin. The hospital serves a payer mix of 31.8% Medicare, 11.6% Medicaid, and 56.6% commercial.

Thesis: Undervalued. Our ML models identify $134.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -10.7% to -3.4% (+736bps).

Net Revenue HCRIS$1.83B
Current EBITDA COMPUTED$-196.6M
Operating Margin COMPUTED-10.7%
Occupancy HCRIS90.1%
Revenue / Bed COMPUTED$8.4M
Net-to-Gross HCRIS29.3%
Distress Probability ML31.4%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
207
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -10.7% places it below the state median. Among 207 size-comparable peers (108-434 beds), the median margin is -4.0%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (108-434), prioritizing same-state peers. 207 hospitals in the comp set.

HospitalStateBedsRevenueMargin
CITY OF HOPE NATIONAL MEDICAL (Target)CA217$1.83B-10.7%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
UCI MEDICAL CENTERCA397$1.90B-2.5%
RADY CHILDRENS HOSPITAL - SAN CA401$1.82B14.8%
HARBOR-UCLA MEDICAL CENTERCA369$1.54B-6.4%
EL CAMINO HOSPITALCA388$1.34B11.7%
CHILDRENS HOSPITAL OF ORANGE CCA334$1.31B0.7%
KFH - SANTA CLARACA343$1.25B12.5%
CHILDRENS HOSPITAL LOS ANGELESCA413$1.21B-36.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $134.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$38.4M+210bp18mo
Cost to Collect4.5%2.5%$36.6M+200bp12mo
Denial Rate Reduction12.0%6.5%$36.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$22.3M+122bp9mo
Clean Claim Rate88.0%96.0%$1.2M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$38.4M
Cost to Collect
$36.6M
Denial Rate Reduction
$36.2M
A/R Days Reduction
$22.3M
Clean Claim Rate
$1.2M
Total EBITDA Uplift$134.7M
Current EBITDA$-196.6M
+ RCM Uplift+$134.7M
Pro Forma EBITDA$-62.0M
Current Margin-10.7%
Pro Forma Margin-3.4%
WC Released (1x)$70.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-302.5M$49.7M0.00x-100.0%
Base (11x exit)10.0x11.0x$-302.5M$-43.5M0.00x-100.0%
Bull Case9.0x11.0x$-272.3M$302.6M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-272.3M$249.8M0.00x-100.0%
Bear Case11.0x10.0x$-332.8M$-525.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-332.8M$-686.0M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 207 hospitals with 108-434 beds
  • Same-state prioritization (n=208)
  • Comp margins: P25=-16.7% / P50=-4.0% / P75=4.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.